Dichotic Listening as a Predictor of Medication Response in Depression
Public ClinicalTrials.gov record NCT00296725. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Dichotic Listening as a Predictor of Placebo and Medication Response in Depression
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Depressed patients will have hearing tests and then be treated with up to three treatments (i.e., Fluoxetine, Imipramine) until remitted, to see whether test results predict specific outcomes.
Study identification
- NCT ID
- NCT00296725
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 25 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 1994
- Primary completion
- May 31, 2011
- Completion
- May 31, 2011
- Last update posted
- May 29, 2019
1994 – 2011
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Depression Evaluation Service, New York State Psychiatric Institute | New York | New York | 10032 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Major Depression trials
Other public records listing Major Depression. Sorted by last update posted; newest first. Not a recommendation.
- NCT07785102: Single Day of Ultra-accelerated TMS With a Single Dose of NRX-101 Not yet recruiting
- NCT06824415: Sleep TMS for Depression Recruiting
- NCT03973268: Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression Recruiting
- NCT07593222: Synaptic Mechanisms of Intermittent Theta Burst Stimulation for Major Depressive Disorder Not yet recruiting
- NCT07560878: Synaptic Mechanisms of Continuous Theta Burst Stimulation in Depression Recruiting
- NCT07226011: Accelerated High-Dose tDCS for Depression Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00296725, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 29, 2019 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00296725 live on ClinicalTrials.gov.